IP Library › Granted Patent US 12,569,557
Granted Patent B2
US 12,569,557 · App. 17/280,986 · Granted Mar 10, 2026

Targeting moDC to enhance vaccine efficacy on mucosal surface

Inventors: Lei Jin (Gainesville, FL); Samira Mansouri (Saratoga Springs, NY)
Assignee: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED
A61K39/39A61K31/708A61K31/7084A61K38/191A61K39/092A61K39/3955A61P31/04A61K2039/543A61K2039/55522A61K2039/55561A61K2039/575
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,569,557
App. No.
17/280,986
Granted
Mar 10, 2026
Kind
B2
Abstract

Described herein are novel vaccine compositions and methods for use thereof in inducing an immune response in a subject especially aged subjects. Specifically exemplified are vaccine compositions that include an antigen; a cyclic dinucleotide; soluble tumor necrosis factor (TNF); or a CD64 antibody or antibody fragment. Optionally, the vaccine composition comprises a TNF conjugated with a moDC targeting moiety in addition to or in place of TNF or CD64 antibody or antibody fragment, or both TNF and CD64 antibody or antibody fragment.

Claims (23)

1 . A vaccine composition comprising a therapeutically effective amount of

an antigen;

a cyclic dinucleotide; and

tumor necrosis factor (TNF) conjugated with a moDC targeting moiety; and, optionally, a CD64 antibody or antibody fragment;

wherein the antigen comprises H7HA, H7N7, PspA, influenza nucleoprotein (NP), HIVenvV1V2 or HIV-1pr55Gag.

2 . The vaccine composition of claim 1 , wherein the cyclic dinucleotide comprises cyclic-di-GMP (CDG), cyclic-di-AMP (CDA), cyclic-di-IMP (CDI), cyclic-AMP-GMP (CDA/G), cyclic-AMP-IMP (CDA/I, and cyclic-GMP-IMP (CDG/I).

3 . The vaccine composition of claim 1 , wherein the CD64 antibody or antibody fragment is a monoclonal antibody.

4 . The vaccine composition of claim 1 , wherein the vaccine composition further comprises a pharmaceutically acceptable carrier.

5 . The vaccine composition of claim 1 , wherein the TNF conjugated with a moDC targeting moiety comprises an anti-CD64 antibody conjugated-TNF and/or Fc conjugated TNF.

6 . A method of eliciting an immune response in a subject comprising administering to the subject a vaccine composition of claim 1 .

7 . The method of claim 6 , wherein the immune response comprises activation of monocyte derived dendritic cells (moDCs).

8 . A kit comprising an inhalative administration device and the vaccine composition of claim 1 .

9 . The kit of claim 8 , wherein the vaccine composition is provided in container separate to the inhalative administration device.

10 . The kit of claim 8 , wherein the vaccine composition is disposed within the inhalative administration device.

11 . A method for treating, or preventing, a disease or condition in a subject, the method comprising

administering to the subject the composition of claim 1 .

12 . The method of claim 11 , wherein the disease or condition comprises cancer or an infection.

13 . The adjuvant composition of claim 1 wherein the composition comprise a CD64 antibody or antibody fragment.

14 . The adjuvant composition of claim 13 , further comprising a pharmaceutically acceptable carrier.

15 . An adjuvant composition comprising TNF conjugated with an moDC targeting moiety.

16 . The adjuvant composition of claim 15 , wherein the moDC targeting moiety comprises Fc of an IgG2a antibody isotype.

17 . The adjuvant composition of claim 15 wherein TNF is sTNF or tmTNF.

18 . The adjuvant composition of claim 17 , wherein tmTNF binds only TNFR2.

Assignments (3)
CONFIRMATORY LICENSE Recorded Nov 22, 2023
From: UNIVERSITY OF FLORIDA
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 065666/0428 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 2, 2021
From: MANSOURI, SAMIRA
To: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED
Reel/Frame 057991/0034 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 14, 2021
From: JIN, LEI
To: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED
Reel/Frame 055918/0073 →
Continuity (2)
Provisional Application 62737154 · Sep 27, 2018
Related Publication 20210353748A1 · Nov 18, 2021
References Cited (57)
US 20140057319A1 · Naso et al. · 2014 [cited by applicant]
US 20160175427A1 · Weiner et al. · 2016 [cited by applicant]
US 20170095548A1 · Malouin et al. · 2017 [cited by applicant]
WO 2016203025A1 · 2016 [cited by applicant]
WO 2017100305A2 · 2017 [cited by applicant]
WO WO2018053508A1 · 2018 [cited by examiner]
WO WO2018140831A2 · 2018 [cited by examiner]
WO WO2019084060A1 · 2019 [cited by examiner]
WO 2020069375A1 · 2020 [cited by applicant]
PCT/US2019/053548, Search report and written opinion, mailed Feb. 19, 2020, 14 pages. [cited by applicant]
Baratin, Myriam et al., “Homeostatic NF-kB Signaling in Steady-State Migratory Dendritic Cells Regulates Immune Homeostasis and Tolerance”, Immunity, Apr. 21, 2015, vol. 42, pp. 627-639. [cited by applicant]
Blaauboer, Steven M. et al., “MPYS/STING-Mediated TNF-, Not Type I IFN, Is Essential for the Mucosal Adjuvant Activity of (3′-5′)-)-Cyclic-Di-Guanosine-Monophosphate In Vivo”, J Immunol, 2014, vol. 192, pp. 492-502. [cited by applicant]
Blaauboer, Steven et al., “The mucosal adjuvant cyclic di-GMP enhances antigen uptake and selectively activates binocytosis-efficient cells in vivo”, eLife, 2015, vol. 4, e06670, 25 pages. [cited by applicant]
Burdette, Dara L. et al., “STING is a direct innate immune sensor of cyclic di-GMP”, Nature, Oct. 27, 2011, vol. 478, pp. 515-519. [cited by applicant]
Caton, Michele L. et al., “Notch—RBP-J signaling controls the homeostasis of CD8—dendritic cells in the spleen”, Jem, Jul. 9, 2007, vol. 204, No. 7, pp. 1653-1664. [cited by applicant]
Crowley, M. et al., “The Cell Surface of Mouse Dendritic Cells: FACS Analyses of Dendritic Cells from Different Tissues Including Thymus”, Cellular Immunology, 1989, vol. 118, pp. 108-125. [cited by applicant]
Dempsey, Alan et al., “Innate immune recognition of DNA: A recent history”, Virology, 2015, vol. 479, No. 480, pp. 146-152. [cited by applicant]
De Silva, Nilushi S. et al., “Impairment of Mature B Cell Maintenance upon Combined Deletion of the Alternative NF-kB Transcription Factors RELB and NF-kB2 in B Cells”, J Immunol, 2016, vol. 196, pp. 2591-2601. [cited by applicant]
Ebensen, Thomas et al., “The Bacterial Second Messenger cdiGMP Exhibits Promising Activity as a Mucosal Adjuvant”, Clinical and Vaccine Immunology, Aug. 2007, vol. 14, No. 8, pp. 952-958. [cited by applicant]
Erickson, Sharon L. et al., “Decreased sensitivity to tumour-necrosis factor but normal T-cell development in TNF receptor-2-deficient mice”, Nature, Dec. 8, 1994, vol. 372, pp. 560-563. [cited by applicant]
Gogoi, Himanshu et al., “New MoDC-Targeting TNF Fusion Proteins Enhance Cyclic Di-GMP Vaccine Adjuvanticity in Middle-Aged and Aged Mice”, Frontiers in Immunology, Aug. 2020, vol. 11, article 1674, 13 pages. [cited by applicant]
Gray, Peter M. et al., “Evidence for cyclic diguanylate as a vaccine adjuvant with novel immunostimulatory activities”, Cellular Immunology, 2012, vol. 278, pp. 113-119. [cited by applicant]
Grell, Matthias et al., “The Transmembrane Form of Tumor Necrosis Factor Is The Prime Activating Ligand of the 80 kDa Tumor Necrosis Factor Receptor”, Cell, Dec. 1, 1995, vol. 83, pp. 793-802. [cited by applicant]
Grell, Matthias et al., “The type 1 receptor (CD120a) is the high-affinity receptor for soluble tumor necrosis factor”, Proc. Natl. Acad. Sci., Jan. 1998, vol. 95, pp. 570-575. [cited by applicant]
Guilliams, Martin et al., “Unsupervised High-Dimensional Analysis Aligns Dendritic Cells across Tissues and Species”, Immunity, 2016, vol. 45, pp. 669-684. [cited by applicant]
Hanson, Melissa C. et al., “ Nanoparticulate STING agonists are potent lymph node-targeted vaccine adjuvants”, J Clin Invest., 2015, vol. 125, No. 6, pp. 2532-2546. [cited by applicant]
Hildner, Kai et al., “Batf3 Deficiency Reveals a Critical Role for CD8a + Dendritic Cells in Cytotoxic T Cell Immunity”, Science, Nov. 14, 2008, vol. 322, pp. 1097-1100. [cited by applicant]
Holt, P.G. et al., “Dendritic Cells in the Respiratory Tract”, International Reviews of Immunology, 1990, vol. 6, No. 2, article 3, pp. 139-149. [cited by applicant]
Hu, Dong-Liang et al., “cdiGMP as a vaccine adjuvant enhances protection against systemic methicillinresistant [cited by applicant]
Jin, Lei et al., “STING/MPYS Mediates Host Defense against Listeria monocytogenes Infection by Regulating Ly6C hi Monocyte Migration”, J Immunol, 2013, vol. 190, pp. 2835-2843. [cited by applicant]
Jin, Lei et al., “MPYS Is Required for IFN Response Factor 3 Activation and Type I IFN Production in the Response of Cultured Phagocytes to Bacterial Second Messengers Cyclic-di-AMP and Cyclic-di-GMP”, J Immunol, 2011, … [cited by applicant]
Karaolis, David K.R. et al., “Cyclic Di-GMP Stimulates Protective Innate Immunity in Bacterial Pneumonia”, Infection and Immunity, Oct. 2007, vol. 75, No. 10, pp. 4942-4950. [cited by applicant]
Klein, Ulf et al., “Transcription factor IRF4 controls plasma cell differentiation and class-switch recombination”, Nature Immunology, Jul. 7, 2006, vol. 7, pp. 773-782. [cited by applicant]
Langlet, Christelle et al., “CD64 Expression Distinguishes Monocyte-Derived and Conventional Dendritic Cells and Reveals Their Distinct Role during Intramuscular Immunization”, J Immunol, 2012, vol. 188, pp. 1751-1760. [cited by applicant]
Libanova, Rimma et al., “Cyclic di-nucleotides: new era for small molecules as adjuvants”, Microbial Biotechnology, 2012, vol. 5, No. 2, pp. 168-176. [cited by applicant]
Lugt, Bryan Vander et al., “Transcriptional programming of dendritic cells for enhanced MHC class II antigen presentation”, Nature Immunology, Feb. 2014, vol. 15, No. 2, 10 pages. [cited by applicant]
Madhun, Abdullah S. et al., “Intranasal cdiGMPadjuvanted plantderived H5 influenza vaccine induces multifunctional Th1 CD4+ cells and strong mucosal and systemic antibody responses in mice”, Vaccine, 2011, vol. 29, pp. … [cited by applicant]
Mansouri, Samira et al., “Lung TNFR2-CD11b+CD24+CD64-DC direct moDCs to generate cyclic di-GMP adjuvant responses in vivo”, Apr. 22, 2018, 56 pages. [cited by applicant]
Metzger, Dennis W. et al., “Limited Efficacy of Antibacterial Vaccination Against Secondary Serotype 3 Pneumococcal Pneumonia Following Influenza Infection”, JID, Aug. 1, 2015, vol. 212, pp. 445-452. [cited by applicant]
Mildner, Alexander et al., “Development and Function of Dendritic Cell Subsets”, Immunity, May 15, 2014, vol. 40, pp. 642-656. [cited by applicant]
Murphy, Kenneth M. “Transcriptional Control of Dendritic Cell Development”, Advances in Immunology, 2013, vol. 120, pp. 239-267. [cited by applicant]
Ogunniyi, Abiodun D. et al., “cdiGMP is an effective immunomodulator and vaccine adjuvant against pneumococcal infection”, Vaccine, 2008, vol. 26, pp. 4676-4685. [cited by applicant]
Pfeffer, Klaus et al., “Mice Deficient fot the 55 kd Tumor Necrosis Factor Receptor Are Resistant to Endotoxic Shock, yet Succumb to L. monocytogenes Infection”, Cell, May 7, 1993, vol. 73, pp. 457-467. [cited by applicant]
Plantinga, Maud et al., “Conventional andMonocyte-DerivedCD11b+Dendritic Cells Initiate and Maintain T Helper 2 Cell-Mediated Immunity to House Dust Mite Allergen”, Immunity, Feb. 21, 2013, vol. 38, pp. 322-335. [cited by applicant]
Schlitzer, Andreas et al., “IRF4 Transcription Factor-Dependent CD11b+ Dendritic Cells in Human and Mouse Control Mucosal IL-17 Cytokine Responses”, Immunity, May 23, 2013, vol. 38, pp. 970-983. [cited by applicant]
Sichien, Dorine et al., “IRF8 Transcription Factor Controls Survival and Function of Terminally Differentiated Conventional and Plasmacytoid Dendritic Cells, Respectively”, Immunity, Sep. 20, 2016, vol. 45, pp. 626-640. [cited by applicant]
Smith, Tyrel T. et al., “Biopolymers codelivering engineered T cells and STING agonists can eliminate heterogeneous tumors”, J Clin Invest., 2017, vol. 127, No. 6, pp. 2176-2191. [cited by applicant]
Steinman, Ralph M., “Decisions About Dendritic Cells: Past, Present, and Future”, Annu. Rev. Immunol., 2012, vol. 30, pp. 1-22. [cited by applicant]
Suzuki, Shoichi et al., “Critical roles of interferon regulatory factor 4 in CD11bhighCD8a2 dendritic cell development”, PNAS, Jun. 15, 2004, vol. 101, No. 24, pp. 8981-8986. [cited by applicant]
Tamoutounour, Samira et al., “CD64 distinguishes macrophages from dendritic cells in the gut and reveals the Th1-inducing role of mesenteric lymph node macrophages during colitis”, Eur. J. Immunol., 2012, vol. 42, pp. 3… [cited by applicant]
Vremec, David et al., “The Surface Phenotype of Dendritic Cells Purified from Mouse Thymus and Spleen: Investigation of the CD8 Expression by a Subpopulation of Dendritic Cells”, J. Exp. Med. Jul. 1992, vol. 176, pp. 47… [cited by applicant]
Wajant, H. et al., “Tumor necrosis factor signaling”, Cell Death and Differentiation, 2003, vol. 10, pp. 45-65. [cited by applicant]
Wallach, D. et al., “Tumor Necrosis Factor Receptor and Fas Signaling Mechanisms”, Annu. Rev. Immunol., 1999, vol. 17, pp. 331-367. [cited by applicant]
Wang, Zili et al., “STING activator c-di-GMP enhances the anti-tumor effects of peptide vaccines in melanoma-bearing mice”, Cancer Immunol Immunother, 2015, vol. 64, pp. 1057-1066. [cited by applicant]
Wu, Jiaxi et al., “Innate Immune Sensing and Signaling of Cytosolic Nucleic Acids”, Annu. Rev. Immunol., 2014, vol. 32, pp. 461-488. [cited by applicant]
Yan, Hongbin et al., “30,50-Cyclic diguanylic acid elicits mucosal immunity against bacterial infection”, Biochemical and Biophysical Research Communications, 2009, vol. 387, pp. 581-584. [cited by applicant]
Zhao, Lisa et al., “c-di-GMP protects against intranasal Acinetobacter baumannii infection in mice by chemokine induction and enhanced neutrophil recruitment”, International Immunopharmacology, 2011, vol. 11, pp. 1378-1… [cited by applicant]